MTOR and glioblastoma: Interestingly, we and others previously showed that inhibition of PI3K/Akt/mTOR-mediated signaling in Glioblastoma cell lines strongly amplifies cell death induced by radiotherapy and a wide range of chemotherapeutics (for example, [14–20]), suggesting that it should be an ideal candidate for targeted combination therapy, i.e. the pairing of a pharmacological inhibitors of cell signaling (sensitizers)–such as the PI3K/mTOR inhibitor PI-103 –with conventional radio- or chemotherapy (inducers).